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Abstract
Background: Cell fusion is a natural process in normal development and tissue regeneration. Fusion between cancer
cells and macrophages generates metastatic hybrids with genetic and phenotypic characteristics from both maternal
cells. However, there are no clinical markers for detecting cell fusion in clinical context. Macrophage-specific antigen
CD163 expression in tumor cells is reported in breast and colorectal cancers and proposed being caused by
macrophages-cancer cell fusion in tumor stroma. The purpose of this study is to examine the cell fusion process
as a biological explanation for macrophage phenotype in breast.
Methods: Monocytes, harvested from male blood donor, were activated to M2 macrophages and co-cultured in
ThinCert transwell system with GFP-labeled MCF-7 cancer cells. MCF7/macrophage hybrids were generated by
spontaneous cell fusion, isolated by fluorescence-activated cell sorting and confirmed by fluorescence microscopy,
short tandem repeats analysis and flow cytometry. CD163 expression was evaluated in breast tumor samples material
from 127 women by immunohistochemistry.
Results: MCF-7/macrophage hybrids were generated spontaneously at average rate of 2 % and showed phenotypic
and genetic traits from both maternal cells. CD163 expression in MCF-7 cells could not be induced by paracrine
interaction with M2-activated macrophages. CD163 positive cancer cells in tumor sections grew in clonal collection
and a cutoff point >25 % of positive cancer cells was significantly correlated to disease free and overall survival.
Conclusions: In conclusion, macrophage traits in breast cancer might be caused by cell fusion rather than explained
by paracrine cellular interaction. These data provide new insights into the role of cell fusion in breast cancer and
contributes to the development of clinical markers to identify cell fusion.
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Background
The theory of cell fusion in cancer states that cancer
cells may produce hybrids with metastatic phenotype
due to spontaneous fusion with migratory leukocytes.
The hybrids acquire genetic and phenotypic characteris-
tics from both maternal cells [1, 2]. Somatic cells acquire
nuclear reprogramming and epigenetic modifications to
form pluripotent hybrid cells without any changes oc-
curring to their nuclear DNA [3]. The direction of nu-
clear reprogramming is decided by the ratio of genetic
material contributed by the maternal cells [4]. Thus, cell
fusion is an efficient process of rapid phenotypic and
functional evolution that produces cells with new prop-
erties at a much higher rate than random mutagenesis.
Several reports present evidence that macrophages are
an important partner in this process. Fusion between mac-
rophages and cancer cells generates hybrids with increased
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metastatic potential [5, 6]. Powell et al. in an experi-
mental animal model with parabiosis, showed in vivo
evidence of fusion between circulating bone-marrow-
derived cells (BMDCs) and tumor epithelium during
tumorigenesis, demonstrating that macrophages were a
cellular partner in this process [7]. Silk et al. (2013)
provided evidence that transplanted cells of the BMDCs
incorporate into human intestinal epithelium through
cell fusion [8]. Circulating hybrids are also reported in
colorectal and pancreatic cancer patients [9].
Based on cell fusion theory and the assumption that the
macrophage–cancer cell fusion creates hybrids expressing
phenotypic characteristics of macrophages, we reported in
previous studies that the macrophage-specific marker,
CD163, was expressed in breast and colorectal cancers.
CD163 expression in cancer cells was significantly related
to advanced tumor stages and poor survival [10, 11]. Fu-
sion events in human cancers are difficult to detect in a
clinical context. Clinically, it is difficult to confirm that
CD163 expression in tumor tissue is caused by cell fusion
because the genetic content of macrophages, cancer cells
and any hybrids have the same origin. Further, the expres-
sion of CD163 in cancer cells could be explained by other
biological processes like abnormal phenotypic expression
in cancer cells and paracrine cellular interaction between
cancer cells and macrophages [12, 13]. To study the clin-
ical significance of cell fusion in breast cancer, it is import-
ant to identify specific markers for this process in clinical
tumor material.
In the present study, we have designed an experimental
model where the presence of macrophage phenotype in
breast cancer cells is examined on the basis of the previ-
ously mentioned arguments. Here we review data that
CD163 expression is caused by cell fusion and not in-
duced by paracrine cellular interaction.
Methods
Cell culture
MCF-7/GFP breast cancer cell line (Cell Biolabs, INC.
San Diego, USA) was cultured in Roswell Park Memorial
Institute (RPMI) 1640 medium supplemented with 1 %
PEST, 10 % FBS, 2.5 % HEPES and 1 % L-glutamine
(Gibco®, Life Technologies, USA) in a T-75 tissue culture
flasks (Sigma-Aldrich Co, ST. Louis, USA) and incu-
bated at 37 °C in humidified air 5 % CO2 atmosphere.
Cell medium was changed every 2–3 days, and the cells
were passaged at 95 % confluence.
Monocyte isolation
Monocytes were isolated from buffy coat obtained from
male healthy blood donors at the department of Trans-
fusion Medicine, County Council of Östergötland, in
Linköping, Sweden. All the blood donors had given
their informed consent according to the local guidelines
(University Hospital in Linköping) and the Swedish Na-
tional Law on ethical review of research involving humans
(2003:460: 3–4 §). The buffy coat was mixed with 70 ml
NaCl, layered onto Lymphoprep (Axis-Shield, Oslo) and
centrifuged at 480 g in room temperature for 40 minutes.
The mononuclear cell layer was collected into new tubes
and washed twice with PBS-Heparin for 5 min and centri-
fuged at 220 g in 4 °C. The white blood cells were seeded
to T-75 tissue culture flasks with RPMI 1640 medium,
supplemented with 1 U/ml penicillin, 10 μg/ml strepto-
mycin and incubated for 1–2 h to allow monocyte adhe-
sion. The non-adherent cells were eliminated by washing
2–3 times using PBS. The adherent monocytes were
allowed to differentiate to macrophages with 40 ng/ml of
macrophage colony-stimulating factor, M-CSF (Nordic
Biosite, Sweden) for 5–7 days. To induce M2 macro-
phages, the M-CSF differentiated macrophages were stim-
ulated with 20 ng/ml human interleukin-4, IL-4 (Nordic
Biosite, Sweden) for 18–24 h.
Cell fusion and cellular interaction model
Green fluorescent protein (GFP) labeled MCF-7 cancer
cells and macrophages were co-cultured in ThinCertTM
cell culture inserts (Greiner Bio One, Kremsmünster, Aus-
teria), where both cell types were allowed to have cellular
interaction without physical contact to prevent cell fusion.
The macrophages (5x105) were seeded in the upper cham-
ber on a polyethylene terephthalate (PET) membrane with
0.4 μm pores and physically separated from MCF-7/GFP
cancer cells that cultured in bottom of the lower chamber.
This cell culture model allows intercellular signaling via
e.g. cytokines and exosomes, which can freely pass through
the PET-membrane pores between the cells (Fig. 1a). It
does not allow cell fusion.
To induce spontaneous cell fusion, macrophages and
GFP-labeled MCF-7 cancer cells were co-cultured in the
same cell culture vial in RPMI 1640 medium during 2–3
days. The cells were seeded at a ratio of about 3–5:1 (mac-
rophages: MCF-7). Cell fusion experiments were repeated
several times, and approximately 5x105 macrophages were
used in each trial. We estimated the size of the population
of hybrids on the basis of the number of macrophages cul-
tured with MCF-7 cancer cells. We did so for a number of
reasons, viz. MCF-7 cancer cells proliferate rapidly, mac-
rophages do not undergo cell division, and we assumed
that a hybrid cell is generated by fusion between a macro-
phage and a cancer cell (Fig. 1b).
Fluorescence-activated cell sorting (FACS)
Cells were washed once with PBS and harvested with a
0.05 % trypsin-EDTA solution. Detached cells were washed
with PBS and resuspended in 95 μl Cell Staining Buffer
(Biolegend, San Diego, USA) at a concentration of about
5x106 cells/ml. The cell suspension was incubated on ice
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for 10 min with 5 μl TrueStain FcX solution (BioLegend,
San Diego, USA) per 1x106 cells. Combinations of direct
conjugated monoclonal anti-human CD163 (APC Anti-
human CD163 (IgG1 k), clone GHI/61, con 100 μg/ml)
and anti-human CD45 (PerCP/Cy5.5 anti-human CD45
(IgG1 k), clone HI30, 50 μg/ml) antibodies or their respect-
ive isotype controls (APC and PerCP/Cy5.5 mouse IgG1 k,
clone MOPC-21, con 200 μg/ml) (Biolegend, San Diego,
USA) were added to the cell suspension at concentrations
recommended by the manufacturer and incubated at 4 °C
in the dark for 30 min. The labeled cells were washed twice
and diluted in 1 ml PBS and filtrated in pre-separation fil-
ter 30 μm (Miltenyi Biotech, Lund, Sweden) before flow
cytometry analysis. Cells in both the ThinCert culture sys-
tem and co-culture were examined initially with a Gallios
flow cytometer (Beckman Coulter, Inc.) and cells were
sorted with BD FACSAria™ III (BD Bioscience, USA). The
cells were examined in relation to GFP, CD163 and CD45
expression. Cells were initially sorted by GFP expression
(positive selection of MCF-7/GFP origin) and subsequently
by CD163 and CD45 expression (positive selection of can-
cer cells with macrophage phenotype).
Immunofluorescence microscopy
Macrophages, MCF-7 cells and hybrids (1x105 cells)
were seeded on coverslips and incubated 24 h in RPMI +
10 % FBS. Cells were fixed with 4 % paraformaldehyde
for 30 min at 37 °C, washed once in PBS followed by
permeabilization/blocking for 30 min in 2 % BSA/0.1 %
Saponin in PBS. Cells were then incubated with a
mouse monoclonal α-CD163 antibody (Abcam) in PBS/
0.5 % BSA for 2 h at room temperature and washed three
times with PBS. A secondary antibody goat anti-mouse
IgG Alexa Fluor 546 (Invitrogen) was added in PBS/0.5 %
BSA for 45 min, followed by three washes with PBS. The
cover slips were mounted on microscope slides in Dako
fluorescence mount media containg DAPI. Fluorescence
images were taken with a Zeiss Axiovert 200 M fluores-
cence microscope with a Zeiss Plan-APOCHROMAT
63x/1.4 oil DIC objective.
Immunostaining and expression levels of CD163 in relation
to survival data
To investigate whether the proportions of CD163 positive
breast cancer cells have been correlated to clinical data, we
re-evaluated breast cancer specimens from 127 women, a
well controlled patient material that was reported in previ-
ous studies [11, 14, 15]. Written informed consent for par-
ticipation in research was obtained from participants in
connection with previous studies. Ethical approval from
the Regional Ethics Committee in Linköping obtained ac-
cording to Swedish Biobank Law (Reference number:
2010/311–31). The patients were diagnosed and treated
using conventional methods at surgical departments in
southeastern Sweden. All patients were in Stage II accord-
ing to the UICC, and all received adjuvant tamoxifen ther-
apy. These specimens had previously been collected in a
tissue microarray and originated from a Swedish random-
ized trial of 2 versus 5 years of tamoxifen treatment. Serial
sections of 5 mm were cut from tissue array blocks, depar-
affinized in xylene, and hydrated in a series of graded alco-
hols (100 %, 95 %, and 70 %). Heat-induced antigen
retrieval was carried out using a water bath pretreatment
in Tris Ethylenediaminetetraacetic acid (1 mM, pH 9) for
50 min before staining for CD163. Detection was carried
out using the DAKO Envision system. The immunoreactiv-
ity of CD163 was characterized by granular cytoplasmic, or
cytoplasmatic and membrane staining patterns. In negative
control samples, the primary antibody was replaced by an
isotype-antimouse immunoglobulin G1 antibody. All im-
munostaining was evaluated by two of the authors (HO
and IS) and scored on a 5-tiered score as follows: 0 %, 1–
25 %, 26–50 %, 51–75 %, and 76–100 % of the cancer cells.
Macrophages and cancer cells could be distinguished on
morphological basis. Macrophage nuclei were small and
regular, whereas the cancer cells were enlarged and
atypical with pleomorphic hypertrophic and darker nu-
clei. Moreover, cancer cells show a decreased cytoplas-
mic - nuclear ratio.
To investigate the significance of CD163 expression
levels in relation to survival data, we used four different
cut-off points 1–25 %, 25–50 %, 50–75 % and 57–100 %
of CD163 positive cancer cells in tumor sections. The cor-
relation of CD163 expression levels and survival rates,
both disease specific survival (DSS) and distant recurrence
Fig. 1 Transwell culture system. The porous bottom of the insert
provides independent access to both sides of a cell monolayer,
allowing in vitro cellular interactions (a). Spontaneous cell fusion was
allowed by culturing MCF-7 cancer cells and M2 macrophages along
the bottom of the same chamber (b)
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free survival (DRFS), was estimated using Kaplan-Meier
analyses and the log rank test.
STR analysis/Quantitative fluorescent PCR
DNA was extracted from macrophage, MCF-7 breast
cancer cells and MCF-7/macrophage hybrid cell suspen-
sions in a biorobot (EZ1, Qiagen) with DNA Tissue kit
(Qiagen) following the manufacturer’s instructions. Each
sample was then subjected to multiplex amplification of
24 STR markers on chromosomes 13, 18, 21, X and Y in
two sets of tubes (Table 1) using ChromoQuant® QF
PCR kit (Cybergene AB). The PCR was carried out in
25 μl reactions containing 14.6 μl mastermix, 0.4 μl
GoTaq polymerase (Promega Inc) and 10 μl DNA (1.5 ng/
μl). An initial denaturation at 94 °C for 3 min was
followed by 26 cycles of 30 seconds at 94 °C, 1 min of an-
nealing at 57 °C, and 2 min of extension at 71 °C. An ex-
tension period of 5 min at 71 °C followed the final cycle.
PCR products were separated by capillary electrophor-
esis on an ABI 3130xl Genetic Analyzer (Applied Biosys-
tems). For each well, 1 μl PCR product was mixed with
12 μl HiDi formamide and 0.3 μl GeneScan-500ROX size
marker, followed by denaturation at 95 °C for 2 min before
loading. The POP7 polymer was used in the electrophor-
esis, and results were analyzed using GeneMapper soft-
ware version 4 (Applied Biosystems).
Results
MCF-7/macrophage hybrid cell generation and transwell
co-culture of macrophages and GFP-labeled MCF-7 cancer
cells
One approach to investigating whether cellular interaction
between the macrophages and cancer cells can induce
macrophage phenotype in cancer cells is to co-culture
both cell types in a transwell culture chamber system.
Macrophages and cancer cells (GFP-labeled MCF-7 cell
line) were co-cultured in the same chamber but separated
by a polyester membrane with 0.4 μm pores to allow cellu-
lar interaction without physical contact to prevent cell fu-
sion (Figs. 1a, 2c-d). We also co-cultured macrophages
and GFP-labeled MCF-7 cancer cells in the same chamber
to create MCF-7/macrophage hybrids by spontaneous cell
fusion (Figs. 1b, 2e-f).
MCF-7/macrophage hybrids were generated spontan-
eously after three days by co-culturing MCF-7 cancer
cells with macrophages. The hybrids were defined as
GFP+/CD163+/CD45+ positive cells and were separated
by FACS. Cells that expressed only GFP were sorted as
MCF-7 cancer cells, and GFP-negative cells were defined
as macrophages. This experiment was repeated several
times, and the proportion of hybrids averaged about 2 %
in each experiment. Flow cytometry analysis showed that
the GFP+ hybrids expressed both the macrophage-
specific marker, CD163, and the leukocyte common anti-
gen, CD45 (Fig. 2e-f ).
As experimental controls MCF-7 cancer cells and mac-
rophages co-cultured for three days in the same medium
in a transwell chamber system were also analyzed by flow
cytometry for GFP, CD163 and CD45 expression. Macro-
phages expressed both CD163 and CD45, but showed no
GFP expression (Fig. 2c). The MCF-7 cancer cells clearly
expressed GFP, but neither CD45 nor CD163 despite re-
peated transwell chamber system experiments (Fig. 2d).
Even when the experiments were repeated with different
durations (3, 5 and 7 days) of co-culture, the outcome
remained the same (data not shown).
Table 1 Size and number of alleles from short tandem repeat
(STR) analysis
STR marker Hybrids Macrophages MCF7 cells
AMEL 105, 110/2 105, 110/2 105/1
DXYS218 323, 327, 331/3 327, 331/2 327/1
SRY 204/1 204/1 -
X22 205, 209, 224/3 205, 224/2 209/1
XHPRT 277, 289/2 277/1 289/1
DXS6803 123, 126/2 126/1 123/1
DXS6854 107/1 107/1 107/1
D13S305 449/1 445, 456/2 448/1
D13S628 455/1 456/1 455/1
D13S634 394, 399/2 394/1 399/1
D13S742 287/1 262, 290/2 286/1
D13S797 196, 200/2 196/1 196, 200/2
D18S386 351, 355, 388, 392/4 355, 388 /2 351, 392/2
D18S390 338, 342/2 342/1 338, 342/2
D18S391 160/1 160/1 160/1
D18S535 475, 483, 487/3 475, 487/2 483/1
D18S819 251, 254, 262/3 251, 254/2 262/1
D18S976 185/1 186, 189/2 185/1
D21S11 253, 267/2 245, 255/2 253, 267/2
D21S1246 293, 297, 318/3 293, 318/2 293, 297/2
D21S1409 203, 210, 214/3 210, 214/2 203, 214/2
D21S1411 307, 312/2 299, 332/2 307, 312/2
D21S1435 375, 383, 387/3 375, 383/2 375, 387/2
D21S1444 314, 318/2 318/1 314, 318/2
STR analysis was used to determine the DNA profile of M macrophages,
GFP-labeled MCF-7 breast cancer cells, and MCF-7/macrophage hybrids. A total
of 24 loci on X and Y chromosomes as well as chromosomes 13, 18 and 21
were used in this analysis. The macrophages originated from M2-activated
monocytes harvested from male blood donors and contained Y chromosome.
MCF-7 is a breast cancer cell line isolated originally from a female patient. Of
24 markers, 17 were of the same allelic size in MCF-7/macrophage hybrids. For
several loci at least one allele was common to macrophages and MCF-7 cancer
cells represented in the hybrids. Sex-determining region Y gene (SRY) is one of
the markers found in MCF-7/macrophage hybrids, indicating that these cells
originate from fusion between macrophages and MCF-7 cells. Note that the
hybrids contain the same size of alleles on the X-chromosome markers as do
macrophages and MCF-7 cells




a) CD45 and b) CD163
d
a b
Fig. 2 Flow cytometry analysis of M2 macrophages, GFP-labeled MCF-7 breast cancer cells and MCF-7/macrophage hybrids. a) M2 macrophages
exhibit CD45 expression when stained with anti-CD45, showing an increase in fluorescence intensity compared to the isotype and negative controls.
b) M2 macrophages exhibit CD163 expression when stained with anti-CD163, showing an increase in fluorescence intensity compared to the isotype
and negative controls. c) The transfected MCF-7 cells exhibit GFP expression. The macrophages were not expressing GFP and no GFP were detected in
macrophages after co-culture in ThinCert transwell culture system. Regardless if macrophages were cultivated over (upper chamber) or under (lower
chamber) GFP-labeled MCF-7 cells in ThinCert transwell cuture system. In this transwell culture system the cells share culture medium, allowing paracrine
signaling, but the cells are physically separated by a filter, preventing cellular contact and cell fusion. d) The MCF-7 cells did not express CD163, nor were
CD163 expression induced after co-culture with macrophages in the ThinCert transwell culture system, indicating that macrophage traits in cancer cells
were not generated by cellular interaction between macrophages and cancer cells. e) Co-cultured MCF-7 cells and macrophages, created hybrids by
spontaneous cell fusion. The hybrids expressed phenotypic characteristics from maternal cells, GFP-labeled MCF-7 breast cancer cells and M2 macrophages.
Note that the hybrids were identified by exhibiting a double positive phenotype, positive for green fluorescence protein GFP and macrophage-specific
antigen CD163, or f) panleukocyte marker CD45
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Fluorescence microscopy
The expression of GFP, CD45 and CD163 in all cell types
was confirmed by fluorescence microscopy. Macrophages,
MCF-7 and hybrids were seeded on glass cover slips and
immunostained for CD163. The hybrids had inherited
GFP expression from MCF-7 cells and CD163 expression
from macrophages. From the transwell culture chamber
system, the macrophages showed distinct expression of
CD163 but not of GFP. The GFP-labeled MCF-7 cells
showed no CD163 expression. The hybrids retained the
MCF-7 cancer cell morphology, which is characterized by
a large nucleus, irregular shape, and a small cytoplasmic
amount (Fig. 3).
DNA profiling
To confirm the origin of hybrids, we used short tandem
repeats (STR) analysis, including loci on X and Y chro-
mosomes as well as chromosomes 13, 18 and 21. The
macrophages were M2-activated monocytes harvested
from male blood donors and contained Y chromosome,
whereas the MCF-7 cell line was derived from a female
breast cancer patient and lacks the Y chromosome. Out
of 24 markers found in macrophages and MCF-7 can-
cer cells, 17 were of the same allelic size in MCF-7/
macrophage hybrids. For several loci, there was at least
one allele common to macrophages and MCF-7 cancer
cells (Table 1). These data represent genomic evidence
that confirm the results from flow cytometry analysis
and indicate that the hybrid cells originate from macro-
phages and the MCF-7 cancer cell line (Fig. 4a).
STR analysis of macrophages and MCF-7 cells grown
in a transwell chamber system showed no shared STR
loci. MCF-7 cells did not show any Y chromosome, con-
firming that cell fusion had not occurred between the
macrophages and MCF-7 cancer cells in the transwell
culture chamber system (Fig. 4b).
Demographics of the MCF-7/macrophage hybrids
Approximately 2 % of hybrids were sorted after each MCF-
7/macrophage hybridization experiment. The hybrids were
isolated and cultured for several weeks. We observed that
the proliferation rate of the hybrids was slower than that of
the parent MCF-7 cells.
Immunohistochemistry and CD163 expression levels in
patient material
To evaluate the frequency of CD163 expression in clinical
tumor material, breast cancer specimens from 127 women
were used. CD163 staining was scored on a 5-tiered score
as follows: 0 %, 1–25 %, 26–50 %, 51–75 %, and 76–100 %
Fig. 3 Fluorescence microscopy. Macrophages, MCF-7/GFP cells and MCF-7/macrophage hybrids, created by spontaneous cell fusion between
GFP-labeled MCF-7 breast cancer cells and M2 macrophages were stained with an α-CD163 antibody and DAPI, and analyzed by fluorescence
microscopy. Cells stained with secondary antibody only were used as negative control for CD163. The hybrids show cytoplasmatic expression
of macrophage-specific antigen CD163 (red) and GFP, which are inherited traits from both maternal cells. Bars = 20 μm
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of the cancer cells. CD163 was expressed in 72 (57 %) pa-
tients. The cancer cells were considerable heterogeneous
in the distribution of CD163 expression in different re-
gions of the same section and in the same tumor speci-
men. CD163 positive cancer cells were organized in a
growth pattern of one or more groups or clonal collec-
tions (Fig. 5a). The proportion of CD163 positive cancer
cells was greater than 50 % in 34 (47 %) of the total of 72
positive tumors (Fig. 5b).
Based on the proportions of cancer cells expressing
CD163, the previously mentioned expression scores were
re-evaluated as cutoff points in assessment of CD163 ex-
pression as a marker in relation to survival data. Patients
with breast tumors expressing CD163 in >25 % of cancer
cells had significantly shorter survival time than patients
with tumors expressing CD163 in <25 % of cancer cells,
which was also reported on in an earlier study [11] (Fig. 6).
Discussion
The genesis of CD163 expression as a macrophage trait in
cancer cells reported in previous clinicohistopathological
studies is unclear. It is proposed to be caused by fusion
between macrophages and cancer cells. Paracrine cellular
interaction in the tumor microenvironment has been sug-
gested as an alternative explanation of macrophage traits
in cancer cells. In the present study, macrophage traits in
MCF-7 cancer cells are only generated by fusion with
macrophages, proving they are not induced by cellular
interaction between the macrophages and cancer cells.
Many reports present evidence that fusion between can-
cer cells and BMDCs, both in vivo and in vitro, may occur
in cancer [7, 16, 17], but evidence of cell fusion and its clin-
ical significance in human cancer remains controversial. Fu-
sion events in human cancers are difficult to detect in a
clinical context due to the lack of clinically safe tracing
methods. The expression of tissue-specific markers, such as
macrophage-specific antigen CD163, by cancer cells can be
a reliable means of detecting the presence and significance
of fusion in tumor tissue from clinical patient material. Sev-
eral clinicopathological studies reported CD163 expression
by cancer cells in breast tumors [11, 14], colorectal [10],
and urinary bladder cancers [18]. CD163 expression was as-
sociated with advanced tumor stages and poor prognosis.
However, these observations in cancer cell phenotype can
be caused by other mechanisms, such as intercellular gen-
etic exchange and paracrine interaction [19].
Transwell experimental in vitro models are well estab-
lished methods of investigating cellular interaction. Such
models have been used to show that breast cancer cells
alter the nature of their surrounding cells, such as fibro-
blasts and macrophages, to support their own progression
through paracrine signaling [20, 21]. Yang et al. reported
that macrophages stimulated by IL-4 regulated the inva-
siveness of breast cancer cells through exosome-mediated
delivery of the oncogenic miR-223 [22]. In this study, the
MCF-7 cancer cells did not acquire macrophage pheno-
type by in vitro interaction with macrophages. MCF-7
cancer cells obtained CD163 and CD45 expression only
by hybridization between MCF-7 cancer cells and macro-
phages. These findings indicate that CD163 expression in
cancer cells can be used as a surrogate marker to detect
cell fusion generally in human solid tumors, and specific-
ally in breast cancer.
Cell fusion is a common biological process that produces
viable cells and plays a major role in mammalian develop-
ment and differentiation [23]. Spontaneous cancer-stromal
cell fusion is a rare, but active, stepwise process that re-
quires the participation of both cell types [24]. In the
present study, the hybrids were generated spontaneously at
an average rate of 2 % and were able to survive cultured in
RPMI 1640 medium for several weeks. Thus, although the
proportion of hybrids may be small in relation to the total
tumor mass, the spontaneity of cell fusion, and the survival
and growth of the hybrids may cause the development of
derivative clones that might have important clinical impli-
cations. It has been postulated that 1 gram of tumor mass
contains approximately 1 x 108 tumor cells [25, 26]. Based
on this calculation, the hybrid rate of 2 % means that each
gram of cancer may contain approximately 2 million hy-
brids. This observation is consistent with the fact that
tumor size is a prognostic factors in breast cancer [27].
Furthermore, fusion efficiency can be proportional to
the malignant level of tumor cells [28]. In this study,
the proportions of CD163 positive cancer cells were
not associated to survival rates. On the other hand, a
cutoff point of >25 % was significantly related to both
disease free and recurrence free survival. These data in-
dicate that CD163 might be useful in clinical context as
(See figure on previous page.)
Fig. 4 Electropherogram of STR analysis evaluates genetic expression in macrophages, MCF-7/GFP and macrophage/MCF-7 hybrid cells. MCF-7/
macrophage hybrids were created by spontaneous fusion between M2 macrophages differentiated from monocytes harvested from male blood
donors and GFP-labeled MCF-7 breast cancer cell. STR analysis with 24 markers on X and Y chromosomes and on chromosomes 13, 18 and 21
was used to determine the DNA profile and origin of the hybrid cells. The figure represents 12 of 17 shared loci detected in MCF-7/macrophage
hybrids as a result of fusion between MCF-7 breast cancer cells and macrophages. The hybrids exhibit sex-determining region Y gene (SRY), which
is an important indicator that these cells have arisen after fusion between macrophages and MCF-7 cells (a). MCF-7 cells from the transwell chamber
system showed no shared STR loci confirming that niether cell fusion nor genetic exchange had occurred between the macrophages and MCF-7
cancer cells (b)
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histopathological marker for detection of fusion between
macrophages and tumor cells in breast cancer.
Cancer is a Darwinian adaptive system where rare genet-
ically unstable cells thwart biological selective pressure
[29]. Clonal expansion is traditionally thought to be driven
by genetic and epigenetic changes inherited by cell division
[30]. Cell-fusion-mediated nuclear reprogramming results
in genetic and epigenetic alterations [31]. The histopatho-
logical analysis in this study clearly shows that CD163-
positive cancer cells are organized in a growth pattern of
one or more collections. Thus, tumor cells with macro-
phage traits may acquire competitive advantages over the
a
b
Fig. 5 Immunostaining of breast cancer tissue sections. Serial breast tumor sections of 5 μm were stained with macrophage-specific antigen
CD163 (Novocastra CD163, clone 10D6, mouse anti-human monoclonal antibody). (a) The histological picture of breast cancer (magnification of ×
200). CD163-positive cells were pleomorphic with large nuclei and showed considerable heterogeneity in the distribution of CD 163 expression in
different regions of the same section and in the same tumor specimens. CD163-positive cancer cells were organized in a growth pattern of clonal
collections (red arrow). CD163-negative cancer cells (blue arrow) show similar morphological pattern but different phenotype (lacking macrophage
phenotype). CD163 positive cancer cells can be distinguished morphologically from tumor associated macrophages. (red interrupted arrow) Note that
macrophage nuclei are small and regular, whereas the cancer cells are enlarged and atypical with pleomorphic nuclei. and decreased cytoplasmic - nuclear
ratio. (b) CD163 was expressed in 57 % of breast tumors. The proportion of CD163-positive cancer cells was greater than 50 % in 34 (47 %) of total 72
positive tumors
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cells in tumor stroma. In the light of these observations
and previous arguments, we believe that cell fusion might
contribute to clonal expansion and the heterogeneity of
cancer cells.
Conclusions
Macrophage traits, represented by CD163 and CD45 ex-
pression in cancer cells, are due to fusion between cancer
cells and macrophages, and cannot be explained by cellular
interaction between these cells. Cell fusion might contrib-
ute to clonal expansion of cancer and generate consider-
able numbers of hybrids in tumor stroma. The cutoff
point >25 % of tumor cells expressing CD163 in tumor
samples is correlated to DSS and DRFS rates suggesting
that CD163 might be useful as macrophage/cancer cell
fusion marker in clinical context.
a
b
CD163  (>25% vs <25%)


































CD163 > 25%  (n=61)
CD163 < 25%  (n=66)
CD163  (>25% vs <25%)




























CD163 < 25%  (n=66)
CD163 > 25%  (n=61)
Fig. 6 Expression levels of CD163 positive cancer cells in breast tumor section from 127 patients. The expression level with a cutoff point of 25 %
of CD163 positive cancer cells in breast tumor sections in association to distant recurrence free survival (a) and disease free survival (b)
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